146464-93-9

Basic information

• Product Name: Benzoic acid, 4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]-
• Synonyms: Benzoic acid, 4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]-;10-Propargyl-4-deoxy-4-amino-10-deazapteroic acid;4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butynyl]benzoic acid;4-(1-(2,4-diaMinopteridin-6-yl)pent-4-yn-2-yl)benzoic acid;Benzoic acid, 4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butynyl]-
• CAS NO: 146464-93-9
• Molecular Formula: C₁₈H₁₆N₆O₂
• Molecular Weight: 348.35864
• Mol File: 146464-93-9.mol

Chemical Properties

• Boiling Point: 642.1±65.0 °C(Predicted)
• Appearance: /
• Density: 1.444
• PKA: 4.15±0.10(Predicted)
• CAS DataBase Reference: Benzoic acid, 4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]-(146464-93-9)
• EPA Substance Registry System: Benzoic acid, 4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]-(146464-93-9)

Safety Data

• Hazardous Substances Data: 146464-93-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of chemical synthesis, Benzoic acid, 4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]serves as a valuable building block for creating more complex molecules with specific properties. Its versatility in chemical reactions makes it a useful compound for researchers and chemists working on the development of new materials and substances.
Used in Research and Development:
Benzoic acid, 4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]is also utilized in research and development for its potential applications in various scientific fields. Its unique structure and properties make it an interesting subject for further study and exploration, which could lead to the discovery of new applications and uses in the future.

InChI:InChI=1S/C18H16N6O2/c1-2-3-12(10-4-6-11(7-5-10)17(25)26)8-13-9-21-16-14(22-13)15(19)23-18(20)24-16/h1,4-7,9,12H,3,8H2,(H,25,26)(H4,19,20,21,23,24)

Upstream product

• 52787-14-1 methyl 4-(2-methoxy-2-oxoethyl)benzoate 
• 52853-40-4 6-bromomethyl-2,4-diaminopteridine hydrobromide 
• 146464-91-7 methyl-4-(2-((2,4-diaminopteridin-6-yl)methyl)-1-methoxy-1-oxopent-4-yn-2-yl)benzoate 
• 146464-90-6 α-propargylhomoterephthalic acid dimethyl ester 
• 146464-92-8 4-(2-carboxy-1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid 
• 1571-08-0 methyl 4-formylbenzoate 
• 1548618-47-8 10-propargyl-10-carbomethoxy-4-deoxy-4-amino-10-deazapteroic acid methyl ester hydrobromide salt 
• 76322-80-0 methyl 4-(3-oxobut-1-enyl)benzoate 

Downstream Products

• 948552-65-6 C₂₃H₂₄N₆O₄ 
• 146464-95-1 pralatrexate 
• 146464-94-0 10-propargyl-10-deazaaminopterin diethyl ester 
• 374777-77-2 10-propargyl-10-deazaaminopterin dimethyl ester 
• 1445586-53-7 lithium 10-propargyl-4-deoxy-4-amino-10-deazapteroate 
• 1445586-50-4 10-propargyl-10-carboxy-4-deoxy-4-amino-10-deazapteroic acid sodium salt 
• 1445586-44-6 potassium 10-propargyl-4-deoxy-4-amino-10-deazapteroate 

Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF PRALATREXATE

An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.

PROCESS FOR PRALATREXATE

The present invention provides a novel process for the purification of alpha-propargylhomoterephthalic acid dimethyl ester substantially free of homoterephthalic acid dimethyl ester. The present invention also provides a novel process for the purification of pralatrexate.

PROCESS FOR PREPARATION OF AN ANTIFOLATE AGENT

The specification relates to a process for preparation of an antifolate compound of formula 7, such as Pralatrexate. Also, disclosed are intermediates and processes for preparation of intermediates useful in the preparation of the antifolate compound. The substituents Y, Z, R, R1 and R2 are as described herein. The processes and intermediates can provide an alternate route to the synthesis of the antifolate compound. Further, the processes can help to avoid distillation or evaporation of high boiling point solvents, chromatographic purification and use of hazardous combination of solvents; and can also provide a product having high purity, all of which are desirable for synthesis on a large scale.

A PROCESS FOR PREPARING INTERMEDIATES OF 10-PROPARGYL-10-DEAZAAMINOPTERIN (PRALATREXATE) SYNTHESIS AND THE INTERMEDIATES THEREOF

A process for preparation of 4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid and other key intermediates in synthesis of 10-propargyl-10-deazaaminopterin (Pralatrexate) and the intermediates thereof. The 10-propargyl-10-deazaaminopterin (Pralatrexate) is obtained by peptide formation and ester hydrolysis of the intermediate compound 4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid by methods known in the art.

PROCESSES AND INTERMEDIATES FOR PREPARING PRALATREXATE

Processes for preparing and purifying Pralatrexate are described in the present application, as well as intermediates in these processes, and salts and solid state forms of the Pralatrexate intermediates.

Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same

The present invention relates to diastereomers of 10-propargyl-10-deazaminopterin, compositions comprising optically pure diastereomers of 10-propargyl-10-deazaminopterin, in particular the two (R,S) diastereomers about the C10 position. Methods of preparation of these diastereomers, compositions containing them, and their use for the treatment of conditions related to inflammatory disorders and cancer are also disclosed.

Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin

T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m2. In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m2 per dose.

Synthesis and in vitro antitumor activity of new deaza analogues of the nonpolyglutamatable antifolate Nα-(4-amino-4-deoxypteroyl)-Nδ- hemiphthaloyl-L-ornithine (PT523)

Details are disclosed for the synthesis of Nα-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]-N δ-hemiphthaloyl-L-ornithine (2) and Nα-[4-[5-(2,4-diaminoteridin-6-yl)pent-1-yn-4-yl]benzoyl]-N δ-hemiphthaloyl-L-

Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors

Preliminary clinical studies in humans have now been done which show both the efficacy of 10-propargyl-10dAM and a preferred dosage schedule for such treatments. In addition, it has now been determined that combinations of 10-propargyl-10-deazaaminopterin

Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors

PCT No. PCT/US97/11982 Sec. 371 Date Mar. 8, 1999 Sec. 102(e) Date Mar. 8, 1999 PCT Filed Jul. 16, 1997 PCT Pub. No. WO98/02163 PCT Pub. Date Jan. 22, 1998Highly purified 10-propargyl-10-deazaaminopterin (10-propargyl-10dAM) compositions tested in xenogra